The circular RNA MICRA improved risk classification for left ventricular ejection fraction groups 4 months after acute myocardial infarction (adjusted OR 0.78).
Observational (n=472)
Does the circular RNA MICRA measured at reperfusion predict left ventricular ejection fraction and risk stratify patients 4 months after acute myocardial infarction?
The circular RNA MICRA measured at reperfusion improves risk stratification for left ventricular dysfunction 4 months after acute myocardial infarction.
Effect estimate: OR 0.78 (95% CI 0.64-0.95)
p-value: p=0.012
BACKGROUND: A significant proportion of patients develop heart failure (HF) after acute myocardial infarction (MI). Predicting this development with novel biomarkers would allow tailoring healthcare to each individual. We recently identified a circular RNA called MICRA which was associated with HF development after MI. Here, we tested whether MICRA was able to risk stratify MI patients. METHODS: MICRA was assessed in whole blood samples collected at reperfusion in 472 patients with acute MI. Left ventricular ejection fraction (EF) was evaluated by echocardiography at 4 months. Multivariable analyses with ordinal regression were conducted to determine the ability of MICRA to classify patients into 3 EF groups: reduced EF (≤ 40%), mid-range EF (4149%) and preserved EF (≥ 50%). RESULTS: Eighty seven patients (18%) had a reduced EF, 106 (22%) had a mid-range EF and 279 (59%) had a preserved EF at 4 months. MICRA classified patients into EF groups with an adjusted odds ratio 95% confidence interval of 0.78 0.64-0.95. MICRA improved the predictive value of a multivariable clinical model as attested by a decrease of the Akaike Information Criteria (p = 0.012). Bootstrap internal validation confirmed the incremental prognostic value of MICRA. CONCLUSION: We report that the circRNA MICRA improves risk classification after MI, supporting the added value of this novel biomarker in future prognostication strategies.
Salgado‐Somoza et al. (Fri,) conducted a observational in Acute myocardial infarction (n=472). MICRA (circular RNA) measurement vs. Clinical parameters alone was evaluated on Classification into 3 ejection fraction groups (reduced, mid-range, preserved) at 4 months (OR 0.78, 95% CI 0.64-0.95, p=0.012). The circular RNA MICRA improved risk classification for left ventricular ejection fraction groups 4 months after acute myocardial infarction (adjusted OR 0.78).